Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2221 to 2235 of 8933 results

  1. Elamipretide for treating Barth syndrome in people of any age [ID6545]

    Awaiting development Reference number: GID-TA11719 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]

    Awaiting development Reference number: GID-TA11746 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]

    Awaiting development Reference number: GID-TA11778 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Ruxolitinib for treating moderate atopic dermatitis [ID6602]

    Awaiting development Reference number: GID-TA11809 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]

    Awaiting development Reference number: GID-TA11706 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment

    In development Reference number: GID-HTE10011 Expected publication date: TBC

    Health technology evaluations
    In development

  7. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

    Awaiting development Reference number: GID-TA11458 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Oveporexton for treating type 1 narcolepsy [ID6622]

    Awaiting development Reference number: GID-TA11820 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  15 July 2026

    Technology appraisal guidance
    In development

  10. Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624]

    Awaiting development Reference number: GID-TA11816 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]

    Awaiting development Reference number: GID-TA11815 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]

    Awaiting development Reference number: GID-TA11526 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6628]

    Awaiting development Reference number: GID-TA11826 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629]

    Awaiting development Reference number: GID-TA11830 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]

    Awaiting development Reference number: GID-TA10662 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development